2016 Conference on Retroviruses and Opportunistic Infections*

February 22-25, 2016; Boston, Massachusetts
Review Capsule Summaries, download slides, and listen to on-demand audio from an expert-led Webcast covering key studies from Boston.

Clinical Impact of New Data From CROI 2016

Capsules

Randomized study suggests further evaluation of maraviroc in PrEP strategies may be warranted.

Released: February 26, 2016

Greater participant satisfaction with cabotegravir injections administered every 12 weeks vs oral once-daily tablets, but pharmacokinetic analysis suggests shorter dosing interval may be required to provide adequate protection.

Released: March 1, 2016

Nonadherence and lack of efficacy observed in subset of women younger than 21 years of age.

Released: February 26, 2016

Switch to the novel NRTI coformulation FTC/TAF associated with improvements in bone and renal biomarkers.

Released: February 26, 2016

Results in line with earlier findings of EARNEST and SECOND-LINE studies.

Released: February 25, 2016

Intramuscular cabotegravir regimen administered every 4 or 8 weeks showed similar virologic efficacy as oral cabotegravir regimen with mild injection-site reactions.

Released: February 26, 2016

Lopinavir/ritonavir-containing 3-drug ART regimen started in pregnancy associated with significantly lower whole-body bone mineral content in newborns vs zidovudine monotherapy plus single-dose nevirapine with a tenofovir DF/emtricitabine tail.

Released: February 29, 2016

First assessment of dolutegravir activity in pregnant women finds exposures vary within the normal range.

Released: February 26, 2016

Numerous other factors associated with fracture risk, including past fracture or osteonecrosis and lower CD4+ cell count.

Released: February 25, 2016

Efficacy was comparable to that of efavirenz in the overall study group; drug-related AEs, specific CNS events less frequent with doravirine vs efavirenz.

Released: February 26, 2016

Adherence to treatment remains most important predictor of response.

Released: February 29, 2016

BMD recovery rate appears slower in adults aged 25 years and older.

Released: February 26, 2016

At Week 96, incident chronic kidney disease was reported in 0.1% of patients receiving TAF vs 1.6% of patients receiving TDF.

Released: February 29, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by independent educational grants from
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?